Clinical trial · Observational
Validation of Pre-clinical Nano-Based Analgesics in Cells From Human Dorsal Root Ganglia
Validation of Pre-Clinical Nano-Based Analgesics in Cells From Dorsal Root Ganglia
NCT04533919CI-TRIAL-00107351withdrawnClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): 0 participants
Summary
Brief summary (as posted)
This study investigates the pre-clinical nano-based analgesics in cells from human dorsal root ganglia (clusters of neurons). Collecting these neurons may help future research related to safe and effective pain treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Spinal Cord Neoplasm | Spinal Cord Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Biospecimen Collection | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Basic science (dorsal root ganglia collection)
- description
- Patients' leftover dorsal root ganglia samples are collected during standard of care surgery.
- interventionNames
- Procedure: Biospecimen Collection
Primary outcomes (2)
- measure
- Viability assays
- timeFrame
- 3 years
- description
- The Viability outcome measure will be expressed using percentage units. This will be calculated as the percentage of cells in culture that are able to exclude a cell permeable dye (Ethidium homodimer) from their nucleus. Entry of this dye into the nucleus and fluorescent binding to nuclear DNA is indicative of a dead/dying cell. Cultured cells that have undergone control or active nanoemulsion treatment in vitro will be loaded with a fluorescent calcium-sensitive dye and continuously monitored while excitation is evoked with a panel of ion channel agonists. The fold-change in intracellular calcium concentration over baseline in response to such excitation is the outcome measure.
- measure
- Functional assays
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: ---All patients undergoing surgery to resect spinal tumors Exclusion Criteria: ---None
References
Publications (0)
Data not yet available
No reference posted for this study.